Ocular Therapeutix™ to Participate in Two Investor Conferences in September 2015

BEDFORD, Mass.--()--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye, today announced that Amar Sawhney, Ph.D., President and Chief Executive Officer, will participate in two upcoming investor conferences in September including:

  • Citi 10th Annual Biotech Conference
    Panel: Envisioning the Future of Novel Ophthalmic Therapies and Drug Delivery Strategies
    Wednesday, September 9, 2015 at 1:00 p.m. Eastern Time
    The Mandarin Oriental Hotel, New York, NY
  • 2015 Morgan Stanley Global Healthcare Conference
    Wednesday, September 16, 2015 at 1:05 p.m. Eastern Time
    The Grand Hyatt Hotel, New York, NY

A live audio webcast of the corporate presentation at the Morgan Stanley Global Healthcare Conference can be accessed through the Calendar of Events section of the Company's website at investors.ocutx.com. A Replay of the webcast will be available on the Company's website for two weeks following the presentation.

About Ocular Therapeutix, Inc.

Ocular Therapeutix, Inc. (NASDAQ: OCUL) is a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology. Ocular Therapeutix's lead product candidates are in Phase 3 clinical development for post-surgical ocular inflammation and pain and allergic conjunctivitis, and Phase 2 clinical development for glaucoma, and inflammatory dry eye disease. The Company is also evaluating sustained-release injectable anti-VEGF drug depots for back-of-the-eye diseases. Ocular Therapeutix's first product, ReSure® Sealant, is FDA-approved to seal corneal incisions following cataract surgery.

Contacts

Investors:
Ocular Therapeutix, Inc.
Brad Smith
Chief Financial Officer
bsmith@ocutx.com
or
Burns McClellan on behalf of Ocular Therapeutix
Kimberly Minarovich, 212-213-0006
kminarovich@burnsmc.com
or
Media:
Scott Corning
Vice President of Sales and Marketing
scorning@ocutx.com

Contacts

Investors:
Ocular Therapeutix, Inc.
Brad Smith
Chief Financial Officer
bsmith@ocutx.com
or
Burns McClellan on behalf of Ocular Therapeutix
Kimberly Minarovich, 212-213-0006
kminarovich@burnsmc.com
or
Media:
Scott Corning
Vice President of Sales and Marketing
scorning@ocutx.com